Tech Company Financing Transactions
Coherus BioSciences Funding Round
F-Prime Capital, KKR and Lilly Ventures participated in a $55 million Series C venture round for Coherus BioSciences. The round was announced on 5/19/2014.
Transaction Overview
Company Name
Announced On
5/19/2014
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Investors
KKR (Ali Satvat)
Sofinnova Ventures (James Healy)
Proceeds Purpose
The capital resources provided by our investors will allow us to prosecute our development plans, optimize our partnering strategies and deliver essential therapeutics to patients faster.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
333 Twin Dolphin Dr. 600
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Website
Email Address
Not Recorded
Overview
Coherus Biosciences is a leading developer of high-quality biosimilar therapeutics with a robust biosimilar pipeline aimed to improve biologic drugs access.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dennis Lanfear
Chief Financial Officer
Jean-Frederic Viret
Chief Medical Officer
Barbara Finck
Chief Technical Officer
Peter Watler
Executive Vice President
Vince Anicetti
Executive Vice President
Vladimir Vexler
VP - Bus. Development
Erik Wiberg
VP - Sales
Michael Fleming
Browse more venture capital transactions:
Prev: 5/19/2014: Contatta venture capital transaction
Next: 5/19/2014: Infomous venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs